About ProGene
We revolutionize drug design with AI by automating the in-silico process to reduce drug design costs
Our startup
At ProGene, we leverage cutting-edge AI to revolutionize protein design, automating complex workflows through a user-friendly platform. By integrating protein prediction and design into a single streamlined solution, we accelerate innovation, significantly reducing time and costs in drug discovery.
Our Mission
To automate the in-silico phase of protein design using AI, streamlining the process for greater efficiency.
Our Vision
To transform drug development into a faster, more affordable, and widely accessible process through advanced AI tools.
Members
Mahdi Pourmirzaei
Co-founder
Farzaneh Esmaili
Co-founder
Advisory Board
Dong Xu
Scientific Advisor
Curators' Distinguished Professor Fellow, AAAAS, AIMBE Core Faculty, LAS, IDSI, IPG and Director of Digital Biology Lab in University of Missouri.
Jeffery Ruffolo
Business Advisor
Machine Learning Scientist and Head of Protein Design at Profluent, PhD in molecular biophysics at John Hopkins University.
Mohammad Rezaei, PhD
Business Advisor
A scientist and product leader working at the intersection of computational drug discovery, machine learning, and scientific software.
Gyan Srivastava, PhD
Business Advisor
Associate director of Bioinformatics and Data Science group at Alexion, AstraZeneca rare disease.
Guangfu Li, PhD, DVM
Scientific Advisor
Professor in the Departments of Surgery and Immunology, Director of Imaging Center and Biorepository at the University of Connecticut School of Medicine.
Alex Morehead, PhD
Scientific Advisor
A Hopper Postdoctoral Fellow at UC Berkeley’s Lawrence Berkeley National Laboratory.